Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection or genetic predisposition. Paradigm is also exploring proof of concept studies in the use of PPS in respiratory and heart failure indications.
Ticker:
PAR
Exchange:
ASX
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
pentosan polysulfate sodium for subcutaneous injection
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4 indications
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
